Ensartinib hydrochloride (X-396 hydrochloride)

An ALK inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
2mg

￥837.00

670.00

- +
5mg

￥1962.00

1570.00

- +
10mg

￥3162.00

2530.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Ensartinib is a potent and selective inhibitor of anaplastic lymphoma kinase (ALK; IC₅₀ < 0.4 nM in a KINOMEscan kinase activity assay).¹ It reduces ALK autophosphorylation and inhibits endogenous ALK phosphorylation and activation of downstream targets ERK and Akt in H3122 cells. Ensartinib reduces growth of H3122 lung cancer cells harboring gain-of-function ALK-fusion proteins (IC₅₀ = 15 nM) but has no effect on cell growth driven by other mutant kinases or that of non-cancerous HepG2 cells. Ensartinib, at a dose of 25 mg/kg, reduces H3122 xenograft growth with no effect on body weight in nude mice. It is also brain-permeable to a concentration of 65 nM.

1.Lovly, C.M., Heuckmann, J.M., de Stanchina, E., et al.Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitorsCancer Res.71(14)4920-4931(2011)

Protocol

Cell experiment:

For viability experiments, cells are seeded in 96-well plates at 25%-33% confluency and exposed to drugs. The human lung adenocarcinoma cell lines H3122 and H2228 are treated with Ensartinib (10, 30, 100, 300 and 1000 nM). SUDHL-1 lymphoma cells are treated with Ensartinib (5, 10, 30, 100 and 300 nM). SY5Y neuroblastoma cells are treated with Ensartinib (30, 100, 300 and 1000 nM). At 72 hours post Ensartinib addition, Cell Titer Blue Reagent is added and fluorescence is measured on a Spectramax spectrophotometer. All experimental points are set up in hextuplicate replicates and are performed at least two independent times. IC50s are calculated using GraphPad Prism version 5 for Windows. The curves are fit using a nonlinear regression model with a log (inhibitor) vs. response formula[1].

Animal experiment:

Mice[1]Nude mice (nu/nu) are injected with H3122 cells. Once tumors reach an average volume of 450 mm3, a total of 27 athymic mice harboring H3122 tumors are randomized and dosed via oral gavage with 25 mg/kg Ensartinib or the control vehicle. Two, five, and fifteen hours after the single treatment (3 tumors/timepoint/group), mice are sacrificed and serum is collected for assessment of drug concentration using an LC-MS based bioanalytical method[1].

参考文献:

[1]. Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res. 2011 Jul 15;71(14):4920-31.